Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
10-12 December, 2025
Saudi International Ex...Saudi International Expo
Not Confirmed
Not Confirmed
10-12 December, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
10-12 December, 2025
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
DDL Conference
Not Confirmed
Contact SupplierDDL Conference
Industry Trade Show
Not Confirmed
10-12 December, 2025
Saudi International Ex...Saudi International Expo
Industry Trade Show
Not Confirmed
10-12 December, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
10-12 December, 2025
Digital content
NEWS #PharmaBuzz
26 Feb 2024
// BUSINESSWIRE
31 May 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/05/31/2679228/0/en/Trevena-Announces-Receipt-of-Milestone-Payment-From-Partner-in-China-Jiangsu-Nhwa-Pharmaceutical.html
27 Jan 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/01/27/2374446/0/en/Trevena-Announces-Submission-of-New-Drug-Application-in-China-for-OLINVYK-by-its-Partner-Jiangsu-Nhwa-Pharmaceutical.html
16 Nov 2021
// Vanessa Doctor BIOSPACE
https://www.biospace.com/article/alzheimer-s-disease-nasal-vaccine-begins-human-trial/?s=71
28 Jul 2021
// PHARMAFILE
http://www.pharmafile.com/news/583940/complix-and-jiangsu-nhwa-collaborate-treatment-cns-diseases
03 Jun 2020
// GLOBENEWSWIRE
http://www.globenewswire.com/news-release/2020/06/03/2042887/0/en/Trevena-Announces-Advancement-of-Oliceridine-Clinical-Development-in-China-by-Jiangsu-Nhwa-Pharmaceutical-Co.html
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
NH280105 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Lead Product(s): NH280105,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2025
A Study of NH280105 in Healthy Adult Participants
Details : NH280105 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 11, 2025
Details:
NH102 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major.
Lead Product(s): NH102,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2025
Lead Product(s) : NH102,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Study to Evaluate NH102 for Depression
Details : NH102 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 24, 2025
Details:
The partnership focuses on commercializing Teva’s Austedo (deutetrabenazine), FDA-approved for treating tardive dyskinesia and chorea associated with Huntington’s disease.
Lead Product(s): Deutetrabenazine,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Austedo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 26, 2024
Lead Product(s) : Deutetrabenazine,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Partnership
Teva and Jiangsu Nhwa Partner to Promote AUSTEDO® Access in China
Details : The partnership focuses on commercializing Teva’s Austedo (deutetrabenazine), FDA-approved for treating tardive dyskinesia and chorea associated with Huntington’s disease.
Product Name : Austedo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 26, 2024
Details:
Under the license agreement, Nhwa granted a license to develop, manufacture, and commercialize Olinvyk (oliceridine), an opioid medication that is used for the treatment of moderate to severe acute pain in adults, in China.
Lead Product(s): Oliceridine,Inapplicable
Therapeutic Area: Neurology Brand Name: Olinvyk
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: Trevena
Deal Size: $5.5 million Upfront Cash: $2.5 million
Deal Type: Licensing Agreement May 31, 2023
Lead Product(s) : Oliceridine,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Trevena
Deal Size : $5.5 million
Deal Type : Licensing Agreement
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
Details : Under the license agreement, Nhwa granted a license to develop, manufacture, and commercialize Olinvyk (oliceridine), an opioid medication that is used for the treatment of moderate to severe acute pain in adults, in China.
Product Name : Olinvyk
Product Type : Miscellaneous
Upfront Cash : $2.5 million
May 31, 2023
Details:
NH102 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depression.
Lead Product(s): NH102,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 20, 2021
Lead Product(s) : NH102,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Ascending Dose Study of NH102 in Healthy Subjects
Details : NH102 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depression.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 20, 2021
Details:
Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialize the CPABs resulting from this collaboration in Greater China.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Recipient: Complix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 28, 2021
Complix Discovery Development Agreement Jiangsu Develop Alphabody Therapeutics
Details : Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialize the CPABs resulting from this collaboration in Greater China.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 28, 2021
Details:
CY150112 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.
Lead Product(s): CY150112,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2021
Lead Product(s) : CY150112,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CY150112 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 09, 2021
Details:
Mivacurium Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Diseases.
Lead Product(s): Mivacurium Chloride,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Tang-Du Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 16, 2015
Lead Product(s) : Mivacurium Chloride,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Recipient : Tang-Du Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis
Details : Mivacurium Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 16, 2015
Details:
Mivacurium Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Mivacurium Chloride,Midazolam,Ketamine Hydrochloride,Propofol,Remifentanil
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 21, 2014
Lead Product(s) : Mivacurium Chloride,Midazolam,Ketamine Hydrochloride,Propofol,Remifentanil
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mivacurium Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 21, 2014
Details:
Fentanyl is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Fentanyl,Etomidate,Propofol
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 31, 2013
Lead Product(s) : Fentanyl,Etomidate,Propofol
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Combined Use of Etomidate and Propofol in Painless Gastroscopy.
Details : Fentanyl is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 31, 2013
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Jiangsu Nhwa Pharmaceutical is a supplier offers 48 products (APIs, Excipients or Intermediates).
Find a price of Fenofibrate bulk with DMF, CEP, JDMF offered by Jiangsu Nhwa Pharmaceutical
Find a price of Buspirone Hydrochloride bulk with DMF offered by Jiangsu Nhwa Pharmaceutical
Find a price of Lithium Carbonate bulk with CEP offered by Jiangsu Nhwa Pharmaceutical
Find a price of Gabapentin bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Alfentanil Hydrochloride bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Aripiprazole bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Bifonazole bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Carbamazepine bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Ciprofibrate bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Citalopram Hydrobromide bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Clomipramine Hydrochloride bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Clonazepam bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Clozapine bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Dexmedetomidine Hydrochloride bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Doxapram Hydrochloride bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Duloxetine Hydrochloride bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Econazole Nitrate bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Etomidate bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Fentanyl Citrate bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Flumazenil bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Flutrimazole bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Ketoconazole bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Menadione bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Miconazole Nitrate bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Midazolam bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Midazolam Maleate bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Naloxone Hydrochloride bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Naproxen bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Naproxen Sodium bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Nitrazepam bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Olanzapine bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Penehyclidine bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Penfluridol bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Pregabalin bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Propofol bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Quetiapine Hemifumarate bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Riluzole bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Risperidone bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Ropivacaine Mesylate bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Sufentanil Citrate bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Sulpiride bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Tapentadol bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Triazolam bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Vitamin K1 bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Vitamin K2 bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Zaleplon bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Ziprasidone Hydrochloride bulk offered by Jiangsu Nhwa Pharmaceutical
Find a price of Ziprasidone Mesylate bulk offered by Jiangsu Nhwa Pharmaceutical
Share 
